As we start to put together a seeming bottom possibility in the pot stock space, Medipharm Labs Corp (OTCMKTS:MEDIF) is particularly interesting. One new element is that the company just announced its wholly-owned subsidiary, MediPharm Labs Inc., has entered into a four-year strategic alliance with Loyalist College of Applied Arts & Technology for education, training, development and applied research projects in collaboration with its Cannabis Applied Science program, the first post-graduate certificate of its kind in Canada.
“MediPharm Labs is pleased to partner with the forward-thinking team at Loyalist to help shape the future of the cannabis industry through innovative research and by contributing to the development of the next generation of cannabis scientists and professionals,” says Pat McCutcheon, Chief Executive Officer of MediPharm Labs. “The possibilities for unique product development and further advancements in cannabis processing methodologies and technology are very exciting, made possible by uniting our respective skills and expertise through this unique private/public partnership.”
Medipharm Labs Corp (OTCMKTS:MEDIF) bills itself as a company that primarily focuses on producing pharma-grade cannabis oil and concentrates in Canada. It also focuses on providing cannabis contract processing services to licensed producers and growers; supplying cannabis oil to companies for sale under its brand; and supplying raw materials and processing for the creation of ready-to-sell cannabis products. The company was founded in 2015 and is headquartered in Barrie, Canada.
Founded in 2015, MediPharm Labs has the distinction of being the first company in Canada to become a licensed producer for cannabis oil production under the ACMPR without first receiving a cannabis cultivation license.
This expert focus on cannabis concentrates from our cGMP (current Good Manufacturing Practices) and ISO standard clean rooms and critical environments laboratory, allows MediPharm Labs to produce purified, pharmaceutical-grade cannabis oil and concentrates for advanced derivative products. MediPharm Labs has invested in an expert, research-driven team, state-of-the-art technology, downstream extraction methodologies and purpose-built facilities to deliver pure, safe and precisely-dosed cannabis products to patients and consumers. MediPharm Labs’ private label program is a high margin business for the company, whereby it opportunistically procures dry cannabis flower and trim from its numerous product supply partners, to produce proprietary cannabis oil concentrate products for resale globally on a private label basis.
Through its subsidiary, MediPharm Labs Australia Pty. Ltd., MediPharm Labs has also completed its application process with the federal Office of Drug Control to extract and import medical cannabis products in Australia.
Find out when $MEDIF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, MEDIF just announced its wholly-owned subsidiary, MediPharm Labs Inc., has entered into a four-year strategic alliance with Loyalist College of Applied Arts & Technology for education, training, development and applied research projects in collaboration with its Cannabis Applied Science program, the first post-graduate certificate of its kind in Canada.
Traders will note 15% during the past week in terms of shareholder gains in the stock. Furthermore, the company has witnessed a pop in interest, as transaction volume levels have recently pushed 19% beyond what we have been seeing over the larger time frame.
“Loyalist College is very proud to partner with MediPharm Labs,” says Dr. Ann Marie Vaughan, Loyalist College President and CEO. “This alliance demonstrates our capacity to collaboratively support commercially relevant applied research while facilitating student learning experiences. With advanced equipment and analytics, our industry-leading labs support education and training of students and industry personnel, while enhancing innovation, productivity and global competitiveness of industry partners.”
Currently trading at a market capitalization of $497M, MEDIF has a significant war chest ($8.6M) of cash on the books, which compares with about $35.7M in total current liabilities. One should also note that debt has been growing over recent quarters. MEDIF is pulling in trailing 12-month revenues of $32.1M. In addition, the company is seeing recent top-line growth, with sequential quarterly revenues growing at 115.2%. As more color becomes clear on the name, we will review the situation and update our take. Sign-up for continuing coverage on shares of $MEDIF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $MEDIF, either long or short, and we have not been compensated for this article.